Elimination of N-glycosylation by site mutation further prolongs the half-life of IFN-α/Fc fusion proteins expressed in Pichia pastoris
Open Access
- 7 December 2016
- journal article
- research article
- Published by Springer Nature in Microbial Cell Factories
- Vol. 15 (1) , 1-9
Abstract
Interferon (IFN)-α has been commonly used as an antiviral drug worldwide; however, its short half-life in circulation due to its low molecular weight and sensitivity to proteases impacts its efficacy and patient compliance. In this study, we present an IgG1 Fc fusion strategy to improve the circulation half-life of IFN-α. Three different forms of IgG1 Fc fragments, including the wild type, aglycosylated homodimer and aglycosylated single chain, were each fused with IFN-α and designated as IFN-α/Fc-WT, IFN-α/Fc-MD, and IFN-α/Fc-SC, respectively. The recombinant proteins were expressed in Pichia pastoris and tested using antiviral and pharmacokinetic assays in comparison with the commercial pegylated-IFN-α (PEG-IFN-α). The in vitro study demonstrated that IFN-α/Fc-SC has the highest antiviral activity, while IFN-α/Fc-WT and IFN-α/Fc-MD exhibited antiviral activities comparable to that of PEG-IFN-α. The in vivo pharmacokinetic assay showed that both IFN-α/Fc-WT and IFN-α/Fc-MD have a longer half-life than PEG-IFN-α in SD rats, but IFN-α/Fc-SC has the shortest half-life among them. Importantly, the circulating half-life of 68.3 h for IFN-α/Fc-MD was significantly longer than those of 38.2 h for IFN-α/Fc-WT and 22.2 h for PEG-IFN-α. The results demonstrate that the elimination of N-glycosylation by mutation of putative N-glycosylation site further prolongs the half-life of the IFN-α/Fc fusion protein and could present an alternative strategy for extending the half-life of low-molecular-weight proteins expressed by P. pastoris for in vivo studies as well as for future clinical applications.Keywords
Funding Information
- National Basic Research Program of China (2013CB944903, 2012CB825806)
- National Natural Science Foundation of China (81272327, 31571440)
- Fundamental Research Funds for the Central Universities (WK2070000050, WK6030000034)
- Natural Science Foundation of Anhui Province (1508085MH167)
- Education Science Foundation of Anhui Province (KJ2013A099)
- Education Science Foundation of Anhui Province (KJ2014ZD35)
- Hundred Talents Program for Innovation of Hefei (2015)
- higher education revitalization plan project of the Education Department of Anhui Province ([2013]189)
This publication has 28 references indexed in Scilit:
- N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteinsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2016
- Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersBioDrugs, 2015
- Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCVAntiviral Therapy, 2012
- Purification and characterization of human IL-10/Fc fusion protein expressed in Pichia pastorisProtein Expression and Purification, 2012
- High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humansGlycobiology, 2011
- Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine contentBiologicals, 2008
- Optimization of humanized IgGs in glycoengineered Pichia pastorisNature Biotechnology, 2006
- The Development of a Modified Human IFN-α2b Linked to the Fc Portion of Human IgG1 as a Novel Potential Therapeutic for the Treatment of Hepatitis C Virus InfectionJournal of Interferon & Cytokine Research, 2004
- Absence of the Macrophage Mannose Receptor in Mice Does Not Increase Susceptibility toPneumocystis cariniiInfection In VivoInfection and Immunity, 2003
- Antiviral Actions of InterferonsClinical Microbiology Reviews, 2001